These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2491879)

  • 1. von Willebrand factor release induced by endotoxin.
    Gralnick HR; McKeown LP; Wilson OM; Williams SB; Elin RJ
    J Lab Clin Med; 1989 Jan; 113(1):118-22. PubMed ID: 2491879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects.
    Suffredini AF; Harpel PC; Parrillo JE
    N Engl J Med; 1989 May; 320(18):1165-72. PubMed ID: 2496309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of insulin treatment in streptozocin-induced diabetic rats on in vitro platelet function and plasma von Willebrand factor activity and factor VIII-related antigen.
    Winocour PD; Lopes-Virella M; Laimins M; Colwell JA
    J Lab Clin Med; 1985 Sep; 106(3):319-25. PubMed ID: 3928783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimeric analysis of von Willebrand factor before and after desmopressin acetate (DDAVP) administration intravenously and subcutaneously in male beagle dogs.
    Kraus KH; Turrentine MA; Johnson GS
    Am J Vet Res; 1987 Sep; 48(9):1376-9. PubMed ID: 3499101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease.
    Böhm M; Täschner S; Kretzschmar E; Gerlach R; Favaloro EJ; Scharrer I
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):39-45. PubMed ID: 16607078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.
    Mohri H; Hashimoto Y; Yamazaki E; Kanamori H; Okubo T
    Hematopathol Mol Hematol; 1998; 11(2):109-15. PubMed ID: 9608359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M; Kimura A; Chiba Y; Yoshida Y
    Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a His54Gln substitution in von Willebrand factor from a patient with defective binding of factor VIII.
    Rick ME; Krizek DM
    Am J Hematol; 1996 Apr; 51(4):302-6. PubMed ID: 8602631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor.
    Counts RB; Paskell SL; Elgee SK
    J Clin Invest; 1978 Sep; 62(3):702-9. PubMed ID: 308512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cryoprecipitate and plasma on plasma von Willebrand factor multimeters and bleeding time in Doberman Pinschers with type-I von Willebrand's disease.
    Ching YN; Meyers KM; Brassard JA; Wardrop KJ
    Am J Vet Res; 1994 Jan; 55(1):102-10. PubMed ID: 8141483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of von Willebrand factor and ristocetin cofactor activity during atrial fibrillation.
    Kalyoncu U; Dizdar O; Erkan Duman A; Karadag O; Tufan A; Yucel O; Tayfur O; Sen D; Ulger Z; Kepez A; Kocabas U; Haznedaroglu I
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):103-8. PubMed ID: 18160605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
    Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
    Wien Klin Wochenschr; 1999 Mar; 111(5):181-91. PubMed ID: 10226348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.